Clinical trials: Tuberculosis Active, open to volunteers
Tuberculosis
A Step Forward for Unraveling the Immune Mechanisms and Tools for Tuberculosis Spectrum Management
Tuberculosis (TB) is a significant infectious disease worldwide, with millions of people infected and major impact on mortality and public health.
- Trial name
- TB-SPECTRUM (NCT07735754)
- Volunteers
- 940 people, healthy volunteers welcome
- Sponsor
- Irene Latorre Rueda
Tuberculosis, Multidrug Resistant Tuberculosis
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)
The objective of this work is to measure the early bactericidal activity of tedizolid, to compare it with the bactericidal activity of linezolid (reference molecule for the treatment of multidrug-resistant tuberculosis) and with…
- Trial name
- TEDITUB (NCT05534750)
- Testing
- Tedizolid arm (SIVEXTRO®), Linezolid arm (ZYVOXID®), Standard quadruple therapy arm
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Tuberculosis, Tuberculosis (TB)
Artificial Intelligence-driven Tuberculosis Landscape Analysis & Stratification Research
The goal of this observational study is to establish and validate a comprehensive AI-driven clinical decision support system (AI-CDSS) in whole-chain management for pulmonary tuberculosis (TB) patients.
- Conditions
- Pulmonary Tuberculosis, Tuberculosis (TB), Tuberculosis Active
- Trial name
- TB-ATLAS (NCT07611695)
- Where
- 2 sites in China
- Volunteers
- 31,600 people
- Sponsor
- Huashan Hospital
Tuberculosis
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
The A5414 study will evaluate whether treatment for drug-susceptible pulmonary tuberculosis (TB) can be tailored according to a participant's risk of an unfavorable outcome.
- Trial name
- NCT07595042
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 29 sites in Argentina, Australia and 14 more
- Volunteers
- 900 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Linezolid, Tuberculosis Multi Drug Resistant Active
Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global public health. Globally, the World Health Organization (WHO) estimates the number at 400,000 patients with MDR-TB for 2023.
- Conditions
- Linezolid, Tuberculosis Multi Drug Resistant Active, Therapeutic Drug Monitoring (TDM)
- Trial name
- PLOT-TB (NCT07477119)
- Testing
- Linezolid dose personalization based on TDM
- Where
- Guinea
- Volunteers
- 150 people
- Sponsor
- Marco Schiuma
Mycobacterium Infections, Tuberculosis, Multidrug-Resistant
Training Protocol on the Natural History of Tuberculosis
Background: Tuberculosis (TB) is an infectious disease that affects numerous people worldwide. Researchers are interested in actively recruiting individuals with TB for research and treatment studies.
- Conditions
- Mycobacterium Infections, Tuberculosis, Multidrug-Resistant, Latent Tuberculosis, Tuberculosis
- Trial name
- NCT01212003
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with…
- Conditions
- Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
- Trial name
- NCT07170800
- Testing
- JDB0131 100mg, JDB0131 200mg, Delamanid (D)
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- WestVac Biopharma Co., Ltd.
Tuberculosis, Latent Tuberculosis
A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)
This is a prospective, multi-center, open-label, cluster randomized controlled clinical trial conducted in school settings to estimate the non-inferiority effect of 1H3P3 compared with 3HR.
- Trial name
- TB-YOUTH (NCT06022146)
- Testing
- isoniazid and rifapentine, Rifampin and Isoniazid
- Where
- 66 sites in China
- Volunteers
- 3,520 people
- Sponsor
- Huashan Hospital
HIV, Art Therapy
Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir Regimens
This is a prospective, multicenter, open-label, parallel-controlled study. The primary objective is to prospectively explore and compare the virological efficacy of Ainuovirine/Lamivudine/Tenofovir and…
- Conditions
- HIV, Art Therapy, TB - Tuberculosis
- Trial name
- ALT VS TLE (NCT07631897)
- Testing
- Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, Tenofovir, Lamivudine and Efavirenz Disoproxil Fumarate Tablets
- Volunteers
- 60 people
- Sponsor
- Shanghai Public Health Clinical Center
Tuberculosis, Latent Tuberculosis Infection
Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients
The goal of this observational study is to investigate the proportion of Mycobacterium tuberculosis (MTB) infection in school contacts of active tuberculosis (ATB) patients.
- Trial name
- NCT06033807
- Testing
- QuantiFERON-TB Gold (QFT) test
- Where
- 44 sites in China
- Volunteers
- 31,440 people
- Sponsor
- Huashan Hospital
Tuberculosis-related Obstructive Pulmonary Disease
Observation Study on the Efficacy of Yiqi Gubiao Pill in the Treatment of Chronic Obstructive Pulmonary Disease Secondary to Active Pulmonary Tuberculosis
Tuberculosis-related obstructive pulmonary disease (TOPD), as a high-burden disease in most countries, poses difficulties in the diagnosis and treatment of the disease when coexisting, and increases the risk of death for…
- Trial name
- NCT06676800
- Testing
- Yiqi Gubiao pill
- Volunteers
- 74 people
- Sponsor
- Fourth Affiliated Hospital of Xinjiang Medical University
Pulmonary Tuberculoses
Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis
A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults with Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis
- Trial name
- NCT07073638
- Testing
- RESP30TB, HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)
- Where
- South Africa
- Volunteers
- 24 people
- Sponsor
- Thirty Respiratory Limited
Tuberculosis
A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide
A multi-centre, randomized, open-label clinical trial. All treatments will be administered orally (PO) on days 1-14. 15 participants will be recruited into each treatment arm in two sequential cohorts.
- Trial name
- ENABLE (NCT06748937)
- Testing
- Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD, Alpibectir 45 mg OD plus Ethionamide 250 mg OD, Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based
- Where
- South Africa
- Volunteers
- 60 people
- Sponsor
- TASK Applied Science
Tuberculosis Meningitis
Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis
AlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity.
- Trial name
- NCT07350174
- Testing
- HRZE, HRZE plus Alpe375, HRZE plus AlpE500
- Volunteers
- 64 people
- Sponsor
- BioVersys AG